1. Home
  2. CET vs DNTH Comparison

CET vs DNTH Comparison

Compare CET & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CET
  • DNTH
  • Stock Information
  • Founded
  • CET 1929
  • DNTH 2015
  • Country
  • CET United States
  • DNTH United States
  • Employees
  • CET N/A
  • DNTH N/A
  • Industry
  • CET Finance/Investors Services
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • CET Finance
  • DNTH Health Care
  • Exchange
  • CET Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • CET 1.5B
  • DNTH 1.5B
  • IPO Year
  • CET N/A
  • DNTH N/A
  • Fundamental
  • Price
  • CET N/A
  • DNTH $34.75
  • Analyst Decision
  • CET
  • DNTH Strong Buy
  • Analyst Count
  • CET 0
  • DNTH 10
  • Target Price
  • CET N/A
  • DNTH $66.38
  • AVG Volume (30 Days)
  • CET 28.4K
  • DNTH 754.7K
  • Earning Date
  • CET 01-01-0001
  • DNTH 11-06-2025
  • Dividend Yield
  • CET 4.41%
  • DNTH N/A
  • EPS Growth
  • CET N/A
  • DNTH N/A
  • EPS
  • CET 7.40
  • DNTH N/A
  • Revenue
  • CET $27,062,484.00
  • DNTH $4,854,000.00
  • Revenue This Year
  • CET N/A
  • DNTH N/A
  • Revenue Next Year
  • CET N/A
  • DNTH N/A
  • P/E Ratio
  • CET $6.99
  • DNTH N/A
  • Revenue Growth
  • CET 15.78
  • DNTH 17.87
  • 52 Week Low
  • CET $40.24
  • DNTH $13.37
  • 52 Week High
  • CET $52.42
  • DNTH $40.16
  • Technical
  • Relative Strength Index (RSI)
  • CET N/A
  • DNTH 52.60
  • Support Level
  • CET N/A
  • DNTH $33.96
  • Resistance Level
  • CET N/A
  • DNTH $40.16
  • Average True Range (ATR)
  • CET 0.00
  • DNTH 2.05
  • MACD
  • CET 0.00
  • DNTH -0.96
  • Stochastic Oscillator
  • CET 0.00
  • DNTH 13.39

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: